Peptide News Digest

#Trevogrumab

2 stories

Clinical Trials · View digest

Lancet Publishes COURAGE: Regeneron's Trevogrumab Preserved Lean Mass on Semaglutide, but the Garetosmab Combination Had High Dropout

In the Phase 2 COURAGE trial of 975 adults with obesity at 60 U.S. sites, people on semaglutide plus placebo lost 6.6% of their lean mass by week 26; adding trevogrumab 200 mg, an antibody against myostatin (GDF8), reduced that loss by 3.1 percentage points, and adding trevogrumab 400 mg with garetosmab reduced it by 4.5 points. In part B, trevogrumab 75 mg reduced 52-week lean-mass loss by 3.1 points vs. 7.3% on semaglutide plus placebo, while 25 mg did not differ significantly. The garetosmab combination had serious adverse events in 9% of participants, 32% discontinued treatment, 41% had muscle spasms, and both deaths in the trial occurred in that group, though investigators did not find a causal link, The Lancet paper reports.

Clinical Trials · View digest

Regeneron COURAGE Phase 2: Trevogrumab + Semaglutide Doublet Cuts Lean Mass Loss in Half; Triplet with Garetosmab Pushes to 92.6% Fat-Mass Loss

Regeneron's COURAGE Phase 2 data presented at EASD 2025 continue to drive obesity-pipeline conversations. Semaglutide alone produced 6.5% lean mass loss at 26 weeks; sema + trevogrumab 200 mg cut that to 3.3% (~half), and the triplet with garetosmab (anti-activin A) pushed to 2.0% lean mass loss with 92.6% fat-mass loss. The triplet had higher discontinuation for tolerability. Full COURAGE completion is expected late 2026, with Phase 3 initiation likely 2027.